AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16922792 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole or itraconazole (200-400 mg/day) during neutropenic episode, continued for patients on lower steroid doses.
Number of subjects: 100
Study 15195060 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP/DEX (ciprofloxacin/dexamethasone otic suspension) 4 drops twice daily for 7 days
Number of subjects: 599
Study 15195060 — intervention group
Group type: COMPARATOR
Intervention: OFL (ofloxacin otic solution) 5 drops twice daily for 10 days
Number of subjects: 599
Study 11435269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus family intervention
Number of subjects: 0
Study 11435269 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study 9723629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1.25 mg/day)
Number of subjects: 303
Study 9723629 — intervention group
Group type: COMPARATOR
Intervention: Standard adjusted-dose warfarin (INR between 2.0 and 3.0)
Number of subjects: 303
Study 8210254 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) administered as 100 mg/m2 weekly intravenous infusion or 150 mg/m2 fortnightly
Number of subjects: 60
Study 8210254 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride)
Number of subjects: 60
Study 2691484 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate iv (single prophylactic dose)
Number of subjects: 181
Study 2691484 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 181
Study 5313064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 2 mg with sulfadoxine 40 mg, fortnightly
Number of subjects: 38
Study 5313064 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine alone at the recommended dose
Number of subjects: 38
Study 30945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum exercise
Number of subjects: 200
Study 30945074 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 200
Study 29228000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402 (2x10^9 CFU twice daily)
Number of subjects: 49
Study 29228000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 25929604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 140
Study 25929604 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 140
Study 24362611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed printed educational materials followed by mailed feedback
Number of subjects: 0
Study 24362611 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group training followed by feedback
Number of subjects: 0
Study 24362611 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group training only
Number of subjects: 0
Study 24362611 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 0
Study 21270121 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines (Pandemrix, Focetria, FluvalP)
Number of subjects: 575
Study 21270121 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccines (Celvapan)
Number of subjects: 575
Study 21270121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix (adjuvanted)
Number of subjects: 575
Study 21270121 — intervention group
Group type: EXPERIMENTAL
Intervention: FluvalP (adjuvanted)
Number of subjects: 575
Study 21270121 — intervention group
Group type: EXPERIMENTAL
Intervention: Focetria (adjuvanted)
Number of subjects: 575
Study 21270121 — intervention group
Group type: COMPARATOR
Intervention: Overall IBD flare risk after vaccination
Number of subjects: 575
Study 19944317 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg intravenously infused just before reperfusion)
Number of subjects: 45
Study 16704696 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology (FDT)
Number of subjects: 117
Study 16704696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency-oriented perimetry (TOP)
Number of subjects: 117
Study 16704696 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Standard (SS)
Number of subjects: 117
Study 16704696 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Fast (SF)
Number of subjects: 117
Study 16704696 — intervention group
Group type: COMPARATOR
Intervention: Criterion 2 for FDT
Number of subjects: 117
Study 15195724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Seal (polyacid-modified resin composite based fissure sealant)
Number of subjects: 53
Study 15195724 — intervention group
Group type: COMPARATOR
Intervention: Delton FS+ (resin based fluoride fissure sealant)
Number of subjects: 53
Study 11290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Number of subjects: 602
Study 11290435 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil plus leucovorin (5-FU/LV)
Number of subjects: 602
Study 9249209 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. chloramphenicol 30 mg/kg
Number of subjects: 29
Study 9249209 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. chloramphenicol 30 mg/kg
Number of subjects: 29
Study 9249209 — intervention group
Group type: COMPARATOR
Intervention: i.v. chloramphenicol
Number of subjects: 29
Study 9249209 — intervention group
Group type: COMPARATOR
Intervention: i.m. chloramphenicol
Number of subjects: 29
Study 9249209 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. and i.m. chloramphenicol
Number of subjects: 29
Study 8497817 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (33.2 mg)
Number of subjects: 11
Study 8497817 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study 3122515 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrel-releasing IUCD
Number of subjects: 140
Study 3122515 — intervention group
Group type: COMPARATOR
Intervention: Copper releasing IUCD
Number of subjects: 140
Study 29898702 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Number of subjects: 97
Study 29898702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipta®
Number of subjects: 97
Study 29898702 — intervention group
Group type: EXPERIMENTAL
Intervention: HandiHaler®
Number of subjects: 97
Study 28571034 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) initiated at 1 month after surgery
Number of subjects: 64
Study 28571034 — intervention group
Group type: COMPARATOR
Intervention: Control group with DBS initiated at 3 months after surgery
Number of subjects: 64
Study 25703647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ACT1 (alpha connexin carboxy-terminal)
Number of subjects: 0
Study 25703647 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) without ACT1
Number of subjects: 0
Study 25703647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ACT1
Number of subjects: 0
Study 23392368 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc levels
Number of subjects: 293
Study 23392368 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels
Number of subjects: 293
Study 23392368 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin levels
Number of subjects: 293
Study 23392368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphopenia associated with zinc levels
Number of subjects: 293
Study 23392368 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and prolactin concentrations
Number of subjects: 293
Study 21443516 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 400 mg QD
Number of subjects: 126
Study 21443516 — intervention group
Group type: COMPARATOR
Intervention: NVP 200 mg BID
Number of subjects: 126
Study 18502299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 382
Study 18502299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 382
Study 18502299 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycaemic agents
Number of subjects: 382
Study 18502299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 382
Study 18502299 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 382
Study 18502299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII and MDI
Number of subjects: 382
Study 17052555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided catheterization
Number of subjects: 130
Study 17052555 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 130
Study 14516342 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 407
Study 14516342 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 407
Study 14516342 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplant history of hypertension
Number of subjects: 407
Study 14516342 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplant history of supraventricular tachyarrhythmias
Number of subjects: 407
Study 14516342 — intervention group
Group type: EXPERIMENTAL
Intervention: AF development
Number of subjects: 407
Study 10647968 — intervention group
Group type: EXPERIMENTAL
Intervention: FFLTC program
Number of subjects: 68
Study 10647968 — intervention group
Group type: COMPARATOR
Intervention: Seated ROM program
Number of subjects: 68
Study 8680886 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemannan (400 mg orally four times daily)
Number of subjects: 63
Study 8680886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 8680886 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemannan
Number of subjects: 63
Study 1880218 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg to 48 mg once daily
Number of subjects: 15
Study 1880218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7040186 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine dihydrochloride (3 X 8 mg)
Number of subjects: 32
Study 7040186 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (3 X 25 mg)
Number of subjects: 32
Study 31466882 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 204
Study 31466882 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 204
Study 30907291 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 (psychoeducation about PMDD)
Number of subjects: 216
Study 30907291 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 (stereotypic PMDD-information)
Number of subjects: 216
Study 30907291 — intervention group
Group type: COMPARATOR
Intervention: CG (information unrelated to PMDD)
Number of subjects: 216
Study 30321272 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg capsule containing 100 mg seaweed (poly)phenol and 300 mg maltodextrin
Number of subjects: 80
Study 30321272 — intervention group
Group type: COMPARATOR
Intervention: 400 mg maltodextrin placebo control capsule
Number of subjects: 80
Study 26968850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation and cognitive behavioral therapy (CBT) intervention
Number of subjects: 35
Study 26968850 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 35
Study 24272224 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV/370-mAs
Number of subjects: 30
Study 24272224 — intervention group
Group type: COMPARATOR
Intervention: 100-kV/300-mAs
Number of subjects: 30
Study 21769512 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI) training and support from the research team for 13 months
Number of subjects: 69
Study 21769512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RAI training)
Number of subjects: 69
Study 21769512 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI) training
Number of subjects: 69
Study 20674774 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Arm 1)
Number of subjects: 4675
Study 20674774 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated support (Arm 2)
Number of subjects: 4675
Study 20674774 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated and assisted support (Arm 3)
Number of subjects: 4675
Study 20674774 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, assisted, and care management support (Arm 4)
Number of subjects: 4675
Study 20674774 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for patients with positive FOBT or adenomas)
Number of subjects: 4675
Study 20674774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse care management (for patients with positive FOBT or adenomas)
Number of subjects: 4675
Study 17509067 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 34
Study 17509067 — intervention group
Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 34
Study 11034037 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care with input from a clinical pharmacist
Number of subjects: 1054
Study 11034037 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 1054
Study 9312196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent slow-release sodium fluoride (SRNaF, 25 mg B.I.D.) plus calcium citrate (400 mg Ca B.I.D.)
Number of subjects: 75
Study 9312196 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus calcium citrate (400 mg Ca B.I.D.)
Number of subjects: 75
Study 8369129 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 100
Study 8369129 — intervention group
Group type: COMPARATOR
Intervention: customary treatments
Number of subjects: 100
Study 3749390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.15 mg/kg)
Number of subjects: 10
Study 3749390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31738192 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy (n = 10)
Number of subjects: 20
Study 31738192 — intervention group
Group type: COMPARATOR
Intervention: In-person delivered exercise therapy (n = 10)
Number of subjects: 20
Study 29237228 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 35
Study 29237228 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 35
Study 29237228 — intervention group
Group type: COMPARATOR
Intervention: Both MTX and AZA
Number of subjects: 35
Study 26370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50,000 U administered 30 min prior to CA
Number of subjects: 138
Study 26370061 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and n-acetyl cysteine before CA
Number of subjects: 138
Study 26370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CC)
Number of subjects: 138
Study 26370061 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-gelatinase-associated-lipocalin (NGAL)
Number of subjects: 138
Study 25466429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 8
Study 25466429 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (60 mg)
Number of subjects: 8
Study 25466429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23586514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulverized lanthanum carbonate (LC) chewable preparation
Number of subjects: 41
Study 23586514 — intervention group
Group type: COMPARATOR
Intervention: Other patients (not NC group)
Number of subjects: 41
Study 20525842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 6 months
Number of subjects: 563
Study 18513259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 40
Study 18513259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16635791 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (Thymoglobulin)
Number of subjects: 0
Study 14529098 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-albuterol delivered via Autohaler (1, 2, or 4 puffs)
Number of subjects: 39
Study 14529098 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-albuterol delivered via P&B (1 or 2 puffs)
Number of subjects: 39
Study 14529098 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo Autohaler (2 puffs)
Number of subjects: 39
Study 14529098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active inhalers (Autohaler and P&B)
Number of subjects: 39
Study 11127933 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticytokine antibodies, cytokines or cytokine-modifying agents
Number of subjects: 0
Study 8803588 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg orally (first dose) 2-4 hours after starting thrombolysis, increased up to 25 mg every 8 hours.
Number of subjects: 45
Study 8803588 — intervention group
Group type: COMPARATOR
Intervention: Placebo after thrombolysis.
Number of subjects: 45
Study 1379009 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HAES 130/0.5
Number of subjects: 45
Study 1379009 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HAES 200/0.5
Number of subjects: 45
Study 1379009 — intervention group
Group type: COMPARATOR
Intervention: Control (no volume therapy)
Number of subjects: 45
Study 31444839 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 129
Study 29764902 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention facilitated by laywomen for 3 years
Number of subjects: 30187
Study 29764902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30187
Study 27706526 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning software
Number of subjects: 39
Study 27706526 — intervention group
Group type: COMPARATOR
Intervention: Control group (procedure video)
Number of subjects: 39
Study 24446955 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation sessions (3 successive monthly sessions)
Number of subjects: 0
Study 24446955 — intervention group
Group type: COMPARATOR
Intervention: Routine seizure clinic follow-up visits
Number of subjects: 0
Study 22721576 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 900
Study 22721576 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR
Number of subjects: 900
Study 22721576 — intervention group
Group type: COMPARATOR
Intervention: Medical and balloon aortic valvuloplasty
Number of subjects: 900
Study 20515982 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (MECC)
Number of subjects: 99
Study 19035244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual microincision cataract surgery (MICS)
Number of subjects: 280
Study 19035244 — intervention group
Group type: COMPARATOR
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 280
Study 16801644 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (n = 17)
Number of subjects: 34
Study 16801644 — intervention group
Group type: COMPARATOR
Intervention: Generic antioxidant treatment (n = 17)
Number of subjects: 34
Study 14662572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiding group (263 children, 69.6%)
Number of subjects: 378
Study 14662572 — intervention group
Group type: COMPARATOR
Intervention: Nonhiding group (115 children, 30.4%)
Number of subjects: 378
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension
Number of subjects: 0
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronary heart disease
Number of subjects: 0
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive men
Number of subjects: 0
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with coronary heart disease
Number of subjects: 0
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly men (general)
Number of subjects: 0
Study 10808681 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women (general)
Number of subjects: 0
Study 10808681 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8797615 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from patients diagnosed with sepsis or septic shock
Number of subjects: 32
Study 8797615 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from patients diagnosed with septic shock
Number of subjects: 32
Study 1622948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Anterior fistula fashioned entirely in corneal tissue
Number of subjects: 78
Study 1622948 — intervention group
Group type: COMPARATOR
Intervention: Group B - Fistula included cornea and sclera with trabecular meshwork and scleral spur
Number of subjects: 78
Study 1622948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 78
Study 6383833 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d. after six months treatment
Number of subjects: 472
Study 6383833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 6383833 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 472
Study 31632654 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) programme
Number of subjects: 1618
Study 28503930 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet with support (5-week education program and follow-up support through focus groups)
Number of subjects: 32
Study 28503930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 28169260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (setting type)
Number of subjects: 94
Study 28169260 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Type VII)
Number of subjects: 94
Study 28169260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 94
Study 24740137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen 400 mg powder for oral suspension (daily dose 800 mg)
Number of subjects: 489
Study 24740137 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg powder for oral suspension (daily dose 1,600 mg)
Number of subjects: 489
Study 24740137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Number of subjects: 489